Demirsoy Ugur, Karadogan Meriban, Selek Özgür, Anik Yonca, Aksu Görkem, Müezzinoglu Bahar, Corapcioglu Funda
Departments of *Pediatric Oncology †Orthopaedics and Traumatology ‡Radiology §Radiation Oncology ∥Pathology, Kocaeli University, Umuttepe, 41380 Kocaeli/Turkey.
J Pediatr Hematol Oncol. 2014 Mar;36(2):156-8. doi: 10.1097/MPH.0000000000000034.
Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB.
骨巨细胞瘤（GCTB）通常是一种具有转移潜能的良性、局部侵袭性肿瘤。GCTB的组织发生尚不清楚，且未发现组织学与临床病程之间存在相关性。因此，许多作者认为其预后不可预测。尽管有多种化疗方案，但GCTB治疗后发生肺转移是众所周知的，且通常预后不佳。地诺单抗可抑制RANK-RANKL相互作用，是GCTB靶向治疗药物中一种新的、有前景的药物。在本报告中，我们强调转移性GCTB对地诺单抗的早期快速反应。
